# A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

> **NCT06649045** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 600 (estimated)

## Conditions studied

- OSA
- Overweight or Obesity

## Interventions

- **DRUG:** Orforglipron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06649045
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-22
- **Primary completion:** 2026-11
- **Final completion:** 2027-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06649045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06649045, "A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06649045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*